Fabio Ynoe de Moraes, Radiation Oncologist and Associate Professor at Queen’s University, shared a post on LinkedIn about a recent article he and his colleague co-authored, adding
“ADRIATIC represents a success of translational science in a disease that has seen few systemic advances for decades. To ensure its benefits are broadly realized, stakeholders should pair clinical implementation with:
Work lead by the superstar: Yuchen Li”
Title: Durvalumab in Limited-Stage Small Cell Lung Cancer: Clinical Triumph and Toward Sustainable Value
Authors: Yuchen Li, Fabio Ynoe de Moraes
Read the Full Article on JCO Global Oncology
More posts featuring SCLC.